Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Apatinib for HCC with PVTT
NCT03261791Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Recurrence-Free Survival at 24 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03261791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03261791.